Pelthos Therapeutics Inc. (PTHS) stock
PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.84−0.31 (-4.34%)
Close on Nov 17, 2026Market cap $26.19MP/E –Yield –
Pelthos Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Pelthos Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 78.6%. For fiscal 2025 it was 76.3%.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 76.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 76.9% | – |
| Q1 FY2026 | Mar 31, 2026 | 84.7% | – |
| Q4 FY2025 | Dec 31, 2025 | 82.2% | – |
| Q3 FY2025 | Sep 30, 2025 | 68.7% | – |
See a number that looks wrong?